Literature DB >> 1310325

Subtypes of betaglycan and of type I and type II transforming growth factor-beta (TGF-beta) receptors with different affinities for TGF-beta 1 and TGF-beta 2 are exhibited by human placental trophoblast cells.

E J Mitchell1, L Fitz-Gibbon, M D O'Connor-McCourt.   

Abstract

Transforming growth factor-beta is likely to be an important factor controlling placental activities, including growth, differentiation, invasiveness, hormone production, and immunosuppression. We have used a chemical cross-linking technique with either 125I-TGF-beta 1 or 125I-TGF-beta 2 and bis(sulfosuccinimidyl) suberate (BS3) to characterize TGF-beta binding components on human placental cells in primary culture. Trophoblast-enriched primary cultures exhibited a predominant affinity-labelled complex characteristic of membrane-anchored betaglycan (formerly termed the Type III TGF-beta receptor) and relatively low levels of the Type I and Type II TGF-beta receptor complexes. The results from affinity labelling saturation and competition experiments with TGF-beta 1 and TGF-beta 2 suggest the existence of two distinct subtypes of betaglycan: one subtype has a lower capacity and higher affinity, binds both TGF-beta 1 and TGF-beta 2, yet has a preferential affinity for TGF-beta 2; the second subtype has a higher capacity and lower affinity and binds TGF-beta 1 exclusively. In contrast, mesenchymal cell-enriched placental primary cultures possessed only one subtype of the betaglycan component that binds the two TGF-beta isoforms with similar affinities and capacities as observed on most cell lines. These experiments demonstrate that the betaglycan component which exhibits a higher affinity for TGF-beta 2 than for TGF-beta 1, that we had observed previously on term placental membranes, is actually present on trophoblast cells. In addition to the two distinctive betaglycan subtypes, subtypes of the Type I and II TGF-beta receptors were detected on the trophoblast-enriched cultures. In competition experiments, when 125I-TGF-beta 1 was used as the radiotracer, the Type I and II TGF-beta receptors show a much higher affinity for TGF-beta 1 than for TGF-beta 2, as observed with other cell types. However, when 125I-TGF-beta 2 was used, low abundance subtypes of both the Type I and II receptors that show similar affinities for TGF-beta 1 and TGF-beta 2 were also revealed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1310325     DOI: 10.1002/jcp.1041500217

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  11 in total

1.  Identification of a structural domain that distinguishes the actions of the type 1 and 2 isoforms of transforming growth factor beta on endothelial cells.

Authors:  S W Qian; J K Burmester; J R Merwin; J A Madri; M B Sporn; A B Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

2.  Transforming growth factor beta may act as an autocrine-survival-promoting factor for transformed trophoblasts.

Authors:  C K Ho; H J Peng; S Y Wang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-04       Impact factor: 2.416

3.  Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent.

Authors:  M M Vilchis-Landeros; J L Montiel; V Mendoza; G Mendoza-Hernández; F López-Casillas
Journal:  Biochem J       Date:  2001-04-01       Impact factor: 3.857

4.  Preventive and therapeutic potential of placental extract in contact hypersensitivity.

Authors:  Youn Son Kim; Jang-June Park; Yukimi Sakoda; Yuming Zhao; Katsuya Hisamichi; Tai-Ichi Kaku; Koji Tamada
Journal:  Int Immunopharmacol       Date:  2010-07-07       Impact factor: 4.932

5.  Characterization of transforming growth factor-beta (TGF-beta) receptors on BeWo choriocarcinoma cells including the identification of a novel 38-kDa TGF-beta binding glycoprotein.

Authors:  E J Mitchell; K Lee; M D O'Connor-McCourt
Journal:  Mol Biol Cell       Date:  1992-11       Impact factor: 4.138

6.  Characterization of distinct functional domains of transforming growth factor beta.

Authors:  J K Burmester; S W Qian; A B Roberts; A Huang; S Amatayakul-Chantler; L Suardet; N Odartchenko; J A Madri; M B Sporn
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

7.  Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos.

Authors:  Kaye L Stenvers; Melinda L Tursky; Kenneth W Harder; Nicole Kountouri; Supavadee Amatayakul-Chantler; Dianne Grail; Clayton Small; Robert A Weinberg; Andrew M Sizeland; Hong-Jian Zhu
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

Review 8.  Transforming growth factor Beta family: insight into the role of growth factors in regulation of fracture healing biology and potential clinical applications.

Authors:  Łukasz A Poniatowski; Piotr Wojdasiewicz; Robert Gasik; Dariusz Szukiewicz
Journal:  Mediators Inflamm       Date:  2015-01-29       Impact factor: 4.711

9.  Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites.

Authors:  F López-Casillas; H M Payne; J L Andres; J Massagué
Journal:  J Cell Biol       Date:  1994-02       Impact factor: 10.539

10.  H19 long noncoding RNA alters trophoblast cell migration and invasion by regulating TβR3 in placentae with fetal growth restriction.

Authors:  Lisa Zuckerwise; Jing Li; Lingeng Lu; Yi Men; Tingting Geng; Catalin S Buhimschi; Irina A Buhimschi; Radek Bukowski; Seth Guller; Michael Paidas; Yingqun Huang
Journal:  Oncotarget       Date:  2016-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.